Volume 64, Pages S84-S93 (December 2003)

Slides:



Advertisements
Similar presentations
Acid-base profile in patients on PD
Advertisements

Volume 59, Issue 4, Pages (April 2001)
Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.
Volume 66, Issue 4, Pages (October 2004)
Buffer transport in peritoneal dialysis
Ex vivo effects of proNGF and NGF on JIA mononuclear cells.
Volume 70, Pages S138-S145 (November 2006)
Acid-base profile in patients on PD
Volume 81, Issue 2, Pages (January 2012)
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis  James F. Medcalf, Kevin P.G.
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
Use of icodextrin in high transport ultrafiltration failure
D. Teta, M. Maillard, G. Halabi, M. Burnier  Kidney International 
Impact of new dialysis solutions on peritonitis rates
Human renal epithelial cells produce the long pentraxin PTX3
Volume 72, Issue 10, Pages (November 2007)
Volume 64, Pages S3-S12 (December 2003)
Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy  G. Viglino, L. Neri, S. Barbieri  Kidney.
Volume 53, Issue 4, Pages (April 1998)
Volume 68, Issue 4, Pages (October 2005)
Yiping Wang, Yuet-Ching Tay, David C.H. Harris  Kidney International 
Regulation of apoptosis by lethal cytokines in human mesothelial cells
Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes1  Joerg Plum, Mohammad.
Volume 14, Issue 6, Pages (June 2001)
Volume 56, Issue 4, Pages (October 1999)
Volume 65, Issue 4, Pages (April 2004)
Volume 63, Issue 1, Pages (January 2003)
High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury  D.P. Gabriel, J.T. Caramori,
S.G. John, N.M. Selby, C.W. McIntyre  Kidney International 
Volume 64, Issue 2, Pages (August 2003)
Regulation of renal proximal tubular epithelial cell hyaluronan generation: Implications for diabetic nephropathy  Stuart Jones, Suzanne Jones, Aled Owain.
Glucose degradation products in peritoneal dialysis fluids: Do they harm?  Janusz Witowski, Achim Jörres, Katarzyna Korybalska, Krzysztof Ksiazek, Justyna.
Volume 73, Pages S5-S17 (April 2008)
Volume 123, Issue 5, Pages (November 2002)
Volume 56, Issue 1, Pages (July 1999)
Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory.
Izabella Z.A. Pawluczyk, Kevin P.G. Harris  Kidney International 
The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions  P.M. ter Wee, R.H.J. Beelen, J.
Volume 54, Issue 6, Pages (January 1998)
Volume 84, Issue 6, Pages (December 2013)
In vitro biocompatibility performance of Physioneal
Volume 81, Issue 2, Pages (January 2012)
Volume 66, Issue 1, Pages (July 2004)
Clifford J. Holmes, Dirk Faict  Kidney International 
Nephrology Crossword: Peritoneal Dialysis
Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function  S.L.S. Fan, T. Pile, S. Punzalan, M.J.
Volume 68, Issue 1, Pages (July 2005)
Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson  Kidney International 
Volume 73, Pages S72-S75 (April 2008)
Volume 64, Issue 6, Pages (December 2003)
Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes  Sr. Anne B. Bakewell, Rob M. Higgins, Mair.
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
Volume 55, Pages S3-S16 (June 1999)
Volume 63, Issue 1, Pages (January 2003)
Biocompatibility of icodextrin
Volume 59, Issue 4, Pages (April 2001)
Volume 56, Issue 1, Pages (July 1999)
Volume 56, Pages S167-S170 (July 1999)
Volume 54, Issue 6, Pages (January 1998)
Charles A. Herzog  Kidney International 
Review of clinical trial experience with icodextrin
Sundararaman Swaminathan, Matthew D. Griffin  Kidney International 
Volume 63, Issue 3, Pages (March 2003)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 61, Issue 2, Pages (February 2002)
Oxalate stimulates IL-6 production in HK-2 cells, a line of human renal proximal tubular epithelial cells  M.E.I. Y.I. Huang, Lakshmi S. Chaturvedi, Sweaty.
Volume 57, Issue 2, Pages (October 2000)
Volume 56, Issue 3, Pages (September 1999)
Clinical Practice Guidelines for Peritoneal Dialysis Adequacy
Presentation transcript:

Volume 64, Pages S84-S93 (December 2003) Clinical indices of in vivo biocompatibility: The role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients  Ruth Mackenzie, Clifford J. Holmes, Suzanne Jones, John D. Williams, Nicholas Topley  Kidney International  Volume 64, Pages S84-S93 (December 2003) DOI: 10.1046/j.1523-1755.2003.08809.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig. 1 Peritoneal macrophage (PMØ) function with increasing dwell time indicates compromised host defense in peritoneal dialysis (PD) patients. The function of PMØ was assessed by measuring both constitutive and lipopolysaccharide (LPS, 100ng/mL)-stimulated TNFα release using enzyme-linked immunosorbent assay (ELISA) in cells isolated from the peritoneal cavity of patients dialyzed with conventional solutions. Data represent the mean (± SD) TNFα release from PMØ isolated from three separate donors. *P < 0.05 vs. 240 minutes, Student t test. Kidney International 2003 64, S84-S93DOI: (10.1046/j.1523-1755.2003.08809.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig. 2 Ex vivo approach to measure peritoneal cell function and effluent markers of membrane integrity and inflammation. Kidney International 2003 64, S84-S93DOI: (10.1046/j.1523-1755.2003.08809.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig. 3 Schematic representation of the events that control peritoneal membrane degeneration in peritoneal dialysis. Arrows indicate the interactions between inflammation, host defense, and the importance of dialysis solution components in modulating cell behavior. Kidney International 2003 64, S84-S93DOI: (10.1046/j.1523-1755.2003.08809.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig. 4 Effect of acute (1-hour) dwell on in vivo peritoneal macrophage function using lactate (40mmol/L lactate, pH 5.2), bicarbonate (38mmol/L bicarbonate), or B/L (25mmol/L bicarbonate/15mmol/L lactate, pH 7.3). Macrophage function is expressed as unstimulated (control) and lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF)α production. Patients were exposed to control on day 1 and then randomized to receive either B on day 2 and B\L on day 3 or B\L on day 2 and B on day 3. Data are presented as mean ± SEM. *P < 0.05 vs. control. Kidney International 2003 64, S84-S93DOI: (10.1046/j.1523-1755.2003.08809.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig. 5 Effect of continuous treatment with lactate (40mmol/L lactate, pH 5.2) or B/L (25mmol/L bicarbonate/15mmol/L lactate, pH 7.3) on the changes in effluent hyaluronic acid levels and interleukin (IL)-6 in overnight timed dwell effluents. Data are presented as mean ± SEM after the run-in phase (t = 0 all patients treated with control solutions) and the treatment phase [at 3 and 6months (t = 3 and t = 6) in patients randomized to control or B/L solutions]. Data comparisons were made with repeated measures analysis of variance (ANOVA). *P < 0.05 vs. 0 time. Kidney International 2003 64, S84-S93DOI: (10.1046/j.1523-1755.2003.08809.x) Copyright © 2003 International Society of Nephrology Terms and Conditions